MDRNA, Inc. Reports Positive Results for its Proprietary siRNA Delivery Technology
News Feb 09, 2010
MDRNA, Inc. has announced that its lead delivery system formulation demonstrated exceptional stability over a one year period under a variety of conditions.
The DiLA2 formulation maintained in vivo knockdown activity with no observed loss in potency over the course of the year-long study when stored under conditions ranging from -80 oC to 4 oC.
In addition, neither change in particle characteristics such as size or charge nor loss in siRNA integrity was observed. The Company's proprietary UsiRNA constructs in the DiLA2 formulations have demonstrated superior activity for delivery to hepatocytes in rodent and non-human primates.
In addition, these compounds have demonstrated inhibition of mRNA via RNAi and subsequent reduction in tumor burden in the Company's oncology programs in liver and bladder cancer. Long-term stability of the DiLA2 formulation/UsiRNA cargo is an integral part of the development of the Company's drug products and represents further progress in these programs.
"The ability of our novel DiLA2 formulation to be stored frozen or at refrigerated conditions is unique," stated Barry Polisky, Ph.D., Chief Scientific Officer at MDRNA, Inc. "We have the flexibility to tailor storage conditions to meet the needs of our internal programs, pharma partners and ultimately the commercial requirements of a marketed RNAi-based therapeutic."
DiLA2 delivery platform is MDRNA's proprietary platform for creating novel liposomal delivery systems based on di-alkylated amino acids (DiLA2). The DiLA2 platform enables MDRNA to tailor the charge, linker length, and acyl chain characteristics to improve delivery of the liposomes to target tissue of interest.
In vivo studies have demonstrated effective delivery in models of metabolic disorders, cancer, and other diseases. DiLA2 based liposomes are well tolerated for repeat dose, and systemic and local administration. MDRNA is also utilizing condensing peptides to form peptide-siRNA nanoparticles to further increase the delivery efficiency of its DiLA2 delivery systems.
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
Machine Learning to Increase the Pace of Brain Imaging AnalysisNews
New approach could allow doctors or researchers to quickly identify the data they need, and then rapidly fill in the fine details, making the process faster and more accurate.READ MORE
University of Huddersfield Honorary Award Goes to RSC’s First Woman PresidentNews
The first woman President of the Royal Society of Chemistry, Professor Lesley Yellowlees, will collect an honorary award from University of Huddersfield, which will be presented at the University’s November Award Ceremonies.READ MORE